Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Aurora Cannabis Inc T.ACB

Alternate Symbol(s):  T.ACB.WS.U | ACB

Aurora Cannabis Inc. is a Canada-based medical cannabis company. The Company's principal business lines are focused on the production, distribution, and sale of cannabis related products in Canada and internationally. The Company’s segments include Canadian Cannabis, European Cannabis and Plant Propagation. The Company's adult-use brand portfolio includes Aurora Drift, San Rafael '71, Daily Special, Whistler, Being and Greybeard, as well as CBD brands, Reliva and KG7. Its medical cannabis brands include MedReleaf, CanniMed, Aurora and Whistler Medical Marijuana Co, as well as international brands, Pedanios, Bidiol and CraftPlant. Its cannabis products are primarily cultivated and manufactured in the facilities in Edmonton, Alberta; Bradford Ontario; Pemberton, British Columbia, and Odense, Denmark. The Company is focused on offering its cannabis products to global medical cannabis market, recreational cannabis market and global hemp-derived cannabidiol (CBD) markets.


TSX:ACB - Post by User

Bullboard Posts
Comment by survivor2015on Jan 29, 2018 12:30am
129 Views
Post# 27452179

RE:RE:I admit, I'm confused!

RE:RE:I admit, I'm confused!
Frankly, I don't see any trust.  The entire document describes in detail what Cannimed can and cannot do.   It gives me the sense it's still a take-over not friendly merger.    I don't think they have any trust in the Cannimed's CEO.

The termination fees are biased towards Aurora. They get to inspect facilities, get trade secrets etc.  In a true merger, things are more mutual.

Breakup fee of  $43.5M is equal even though the market cap is quite different.

The Offer stipulates the law suits have to be retracted but this has not been done? In a friendlier agreement, this would be a #1 priority.  It will be interesting how quickly they move with this?

My head says buy APH until the dust settles on this entire take over.  But here is something very attractive about CMED and I don't think corporate negotiations worry too much about bad blood.  As they say "it's just business".
Bullboard Posts